Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | Pneumococcal Infections Therapeutics – Pipeline Assessment and Market Forecasts to 2017Pneumococcal Infections Market Forecast to Show Moderate Growth until 2017
By: Rajesh Gunnam bacterium. Streptococcus pneumoniae is gram-positive bacteria of which there are approximately 90 identified serotypes. Of these, 23 serotypes are identified as the prime cause of an estimated of 90% cases of invasive pneumococcal disease (IPD), and therefore this report focused on the same causative organism. GlobalData estimates that the global pneumococcal infections market valued $4,620.3m in 2010, and is forecast to grow at a compound annual growth rate (CAGR) of 8.2% over the next seven years, to reach $8,016.2m by 2017. The moderate growth of the market is attributed to the entry of generics into the market. The patents for branded products will expire within the forecast period, such as Zyvox (linezolide) profiles such as torezolid phosphate (TR-701, DA-7218), and the product extension of Prevnar13 for adults is also expected to drive the future market and, to a certain extent, fulfill unmet need. GlobalData found that that the presently available treatment options are successful in meeting the market demand. Newer drugs like Zyvox and Avelox has bought much needed efficacy in the reduction of progression of the disease in infected patients. However the strains have developed resistance towards the class of antibiotics such as β-lactam, glycopeptides, lincosamide, and cephalosporins. Due to these multidrug resistance the use of these antibiotics are declining and the patients have switched from the antibiotics to other classes of drugs like Zyvox and Avelox which has shown improved efficacy. Similarly, the vaccination rate has increased over the last few years due to increase in awareness among parents and the patients. The approved vaccines like Prevnar7, Prevnar13, Synflorix (all in children) and Pneumovax23 (in adult) has proved to be efficacious resulting in declining incidence rate of infection. For Sample Pages, please click or add the below link to your browser: http://www.globaldata.com/ The pneumococcal infections therapeutics market has significant unmet needs of 18% and the pneumococcal infections prophylactic market also has significant unmet need of only 16%. This implies that both therapeutics and prophylactic market is served with current options for treatment of infections. This is because all the currently marketed products are targeted at the treatment of the causative organism, management of disease symptoms and at the recovery of patients. The efficacy of the current prophylactic vaccines in the pneumococcal infections market is good however; there is a scope for new entrant to capitalize on both the market if they come up with multivalent vaccines for prophylactic treatment. The therapeutic market for pneumococcal infections has products with good efficacy and moderate safety profile. The major marketed therapeutics of pneumococcal infections includes classes of antibiotics like B-lactam, cephalosporins, glycopeptides and lincosamide. Other marketed products are Zyvox (linezolide) GlobalData, the industry analysis specialist, has released its new report, “Pneumococcal Infections Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global pneumococcal infections market. The report identifies the key trends shaping and driving the global pneumococcal infections market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global pneumococcal infections sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. For further details, please click or add the below link to your browser: http://www.globaldata.com/ Visit our report store: http://www.globaldata.com/ For more details contact: pressreleases@ North America: +1 646 395 5477 Europe: Asia Pacific: # # # GlobalData is a UK-based company with presence across North America, Europe and Asia Pacific and has a broad product offering that ranges from interactive databases, reports and custom solutions. It is a comprehensive source of insights and analysis with coverage including oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries. End
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number